Jonathan Freeman
Directeur/Membre du Conseil chez PHIO PHARMACEUTICALS CORP.
Fortune : 2 214 $ au 30/06/2024
Profil
Jonathan E.
Freeman is the founder of Anthos Therapeutics, Inc. (founded in 2021) where he holds the title of Chief Operating Officer.
He is currently working as an Independent Director at Phio Pharmaceuticals Corp.
since 2017 and as a Senior Advisor at Blackstone Life Sciences Advisors LLC since 2018.
Previously, he worked as the Director-Mergers & Acquisitions at Baxter Healthcare Corp.
from 2005 to 2008.
He also served as the Director & Vice President at Swiss-PLG.
From 2008 to 2016, he held the position of Senior Vice President & Head-Strategy Development at Merck KGaA.
Prior to that, he was the Head-Licensing at EMD Serono, Inc. from 1999 to 2005.
He also worked as the Chief Business Officer at Vedanta Biosciences, Inc. Dr. Freeman completed his undergraduate and graduate studies at the University of Cambridge and holds an MBA from Webster University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/04/2024 | 3 200 ( 0,07% ) | 2 214 $ | 30/06/2024 |
Postes actifs de Jonathan Freeman
| Sociétés | Poste | Début |
|---|---|---|
| PHIO PHARMACEUTICALS CORP. | Directeur/Membre du Conseil | 07/06/2017 |
Anthos Therapeutics, Inc.
 Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | Fondateur | 01/07/2021 |
Blackstone Life Sciences Advisors LLC
 Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | Consultant / Advisor | 01/11/2018 |
Anciens postes connus de Jonathan Freeman
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK KGAA | Corporate Officer/Principal | 01/01/2016 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 01/01/2008 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01/01/2005 |
| Swiss-PLG | Directeur/Membre du Conseil | - |
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Jonathan Freeman
| University of Cambridge | Graduate Degree |
| Webster University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| PHIO PHARMACEUTICALS CORP. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Swiss-PLG | |
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | Finance |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | Health Technology |
